title: Successful treatment of nasal T-cell lymphoma with a combination of local irradiation and high-dose chemotherapy.
abstract: Nasal natural killer (NK)/T-cell lymphoma is characterized by an aggressive clinical course and poor prognosis. The term "NK/T-cell" lymphoma includes both the NK-cell type and the T-cell type, which are classified by immunophenotyping and according to T-cell receptor (TCR) rearrangement. In addition, CD56+ T-cell lymphoma is defined as NK-like T-cell lymphoma. This report concerns a 54-year-old woman with nasal T-cell lymphoma. Its phenotype showed pure T-cell type with CD3+, CD56-, and TCR+ accompanied by Epstein-Barr virus infection. Although the lesions were localized in the nasal mucosa and facial skin (stage IE), local irradiation could not achieve complete remission (CR). We then administered 5 courses of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) regimen followed by high-dose chemotherapy with an autologous peripheral blood stem cell transplantation. This therapy resulted in CR. Our results suggest that this lymphoma subtype may be cured by means of intensive treatment soon after diagnosis.
authors.affiliation: Second Department of Internal Medicine, Nagoya City University Medical School, Nagoya, Japan.
authors.forename: Takaomi
authors.initials: T
authors.lastname: Sanda
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Lida
authors.forename: Masato
authors.initials: M
authors.lastname: Ito
authors.forename: Kazuya
authors.initials: K
authors.lastname: Tsuboi
authors.forename: Kazuhisa
authors.initials: K
authors.lastname: Miura
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Harada
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Komatsu
authors.forename: Atsushi
authors.initials: A
authors.lastname: Wakita
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Inagaki
authors.forename: Ryuzo
authors.initials: R
authors.lastname: Ueda
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D016399:Lymphoma, T-Cell / Q000628:therapy*; D008875:Middle Aged; D009669:Nose Neoplasms / Q000628:therapy*; D011239:Prednisolone / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant; D012074:Remission Induction; D033581:Stem Cell Transplantation; D014182:Transplantation, Autologous; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone